Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Frequently asked questions
What sector does Inventiva S.A (IVA) operate in?
Inventiva S.A belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Inventiva S.A (IVA) current stock price?
As of the latest data, Inventiva S.A stock price is €4.03, with a previous close of €4.03.
What is Inventiva S.A (IVA) current market capitalization?
Inventiva S.A market cap is approximately 951.97 million.
What is Inventiva S.A (IVA) Earnings Per Share (EPS)?
The trailing EPS is -€1.90, and the forward EPS is -€0.81.
Does Inventiva S.A (IVA) pay dividends?
No. Inventiva S.A does not pay a dividend.
When is Inventiva S.A (IVA) next earnings report?
Inventiva S.A is expected to release its next earnings report on June 30, 2026.
What is Inventiva S.A (IVA) beta (volatility) score?
Inventiva S.A has a beta of 0.913, meaning its volatility is roughly in line with the market.
